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Effect of Hepatic Dysfunction and T Tube Clamping on FK 506 
Pharmacokinetics and Trough Concentrations 
A.B. Jain, R. Venkataramanan, E. Cadoff, J.J. Fung, S. Todo, A. Krajack, and T.E. Starzl 
I N initial clinical trials of organ transplanta.tion, c~K R~ has shown remarkable immunosuppressive activity. 
The drug is very lipophilic. metabolized in the liver, and 
predominantly eliminated through the bile. 2 Hepatic dys-
function was expected to alter the pharmacokinetics of FK 
506. Hepatic dysfunction is also known to alter the absorp-
tion of lipid soluble drugs. 3 This is related to the lack of 
sufficient bile for solubilization of the drug in the gastroin-
testinal tract. Orthotopic liver transplantation (OLT) com-
monly requires temporary external drainage of bile via T 
tube. Clamping and unclamping of the T tube allowing bile 
to be delivered to the gastrointestinal tract or drained 
externally, respectively, could affect the absorption and 
bioavailability of lipid soluble FK 506, as it is known to do 
with CyA. 
The objectives of this study were to examine the effect 
of hepatic dysfunction on the pharmacokinetics of FK 506 
following intravenous and oral doses. to study the effect of 
liver dysfunction on the daily trough concentration of the 
drugs. and to define the effect of T tube clamping and 
unclamping following 0 L T on the absorption and bioavail-
ability of the drug. 
MATERIALS AND METHODS 
Intravenous pharmacokinetic studies were done in patients with 
or without hepatic dysfunction. The patients received 0.15 mg/kg 
of FK 506 as an infusion over I to 2 hours. Blood samples were 
collected for plasma FK 506 concentration measurements at O. ,/,. 
I. 1,/,. 2. 3. 4. 6. 8. 12. 16. 20. and 24 hours after starting the 
infusion. Blood samples were also collected for daily trough FK 
506 measurements just prior to the daily morning dose. Pharma-
cokinetlc studies were also done when the patients received their 
first oral dose of FK SOh (0.15 g kgJ. \Iultiple blood samples were 
obtained over the dosing interval of 12 hours. In one patient. the 
intravenous pharmacokinetics ,tudy was repeated at 1- and 3-
month intervals. by which time there had been improvement in 
hepatic function. Various pharmacokinetic parameters and the 
trough FK '06 concentratiom \I ere compared between patients 
with normal and abnormal liver function. 
The effect of T tube clamping on the oral absorption of FK 506 
was studied in five OL T patients with good liver function who had 
a duct to duct biliarv reconstruction \1 ith a T tube sten!. Multiple 
blood samples were withdrawn at vanous time periods after oral 
administration of FK 506 10.15 mg.'kg) before and after clamping 
the T tube. The amount of bile drainage was recorded. and the 
hepatic function wa~ monilored. 
All blood 'iamples were centrifuged at 37°C after incubation at 
3TC for I hour. and the plasma was analyzed for FK 506 
concentrations by enzyme-linked radioimmunoa~sayK as de-
scribed by Tamura et al· and modified bv Cad off et aI.' Various 
pharmacokinetic parameters (noncompartmental analysis) were 
calculated according to standard techniques. 6 
RESULTS 
HepatiC Function 
Intravenous Pharmacokinetics in All Cases. Patients 
with normal serum bilirubin tended to have low 24-hour 
trough levels after the first intravenous bolus of 0.15 mg/kg 
FK 506. In contrast, jaundiced patients had high trough 
levels (Fig I). 
Intravenous Pharmacokinetics With Liver Dysfunction. 
Five of the most jaundiced patients, who also had other 
evidence of hepatic dysfunction, were studied separately 
(Tables I and 2). Their peak and trough FK 506 levels were 
higher, as shown for a single patient in Fig 2 compared 
with a patient with good hepatic function. In Fig 3, a 
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Fig 1. Twenty-four hour trough plasma concentrations of FK 506 
in relation to serum bilirubin following the first intravenous dose. 
Trough values tended to be higher when serum bilirubin was> 2 
mg/dl. 
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Table 1. Pharmacokinetics of FK 506 Administered 
Intravenously In Five Patients 
Bilirubin ea~-iife Clearance 
Patient (mgldl) (h) (Uh) 
J.G. 17.6 22.4 70.2 
A.N. 2.3 29.9 49.3 
H.W. 12.5 40.1 35.9 
D.S. 18.4 38.8 30.7 
H.M. 21.7 61.5 12.9 
Mean 38.5 39.8 
change in pharmacokinetics is seem in a single patient as 
the liver function improved over a 3-month interval. The 
principal change was a much lower trough level at an 
earlier time after the liver had recovered, although the 
same intravenous dose was given. 
One of the five patients with hepatic dysfunction devel-
oped fulminant hepatic failure due to recurrence of hepa-
titis B (Fig 4). The serum bilirubin increased from 2.2 on 
day 1 to 25.7 mg/dl on day 11. The daily trough plasma FK 
506 concentration increased from 3.4 to 8.2 nglml in 5 
days. FK 506 was discontinued after the morning dose on 
Table 2. Pharmacokinetics of FK 506 Administered Orally 
Bilirubin Trough C Max" Bioavailabilily 
(mgldl) ("9'ml) ("9'ml) (%) 
8.1 7.4 8.0 47 
8.5 7.1 8.7 56 
13.5 4.0 4.0 
17.3 12.4 14.6 21 
17.6 2.4 2.4 21 
Mean 7.5 36 
'C Max. maximum plasma concentration. 
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Fig 2. Typical pharmacokinetic profile following intravenous FK 
506 administration in two patients with bilirubin 0.4 and 2.3 mg/dl. 
A slower fall in plasma concentration is noted after the distribution 
phase in the jaundiced patient. 
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Fig 3. Pharmacokinetic profile of FK 506 after intravenous dosing 
on two separate occasions in the same patient. A rapid fall was 
noticed after the distribution phase as the liver function improved. 
day 5. Even 72 hours after discontinuation of the drug, 
trough plasma concentrations were still 3 ng/m!. 
The mean half-life ofFK 506 was 38.5 hours (22.4 to 61.5 
hours), and the mean clearance was 39.8 (12.9 to 70) Uh in 
the five patients with abnormal liver function. The normal 
half-life is less than 10 hours and the normal clearance is 
about 120 LIh.:! 
Oral Kinetics in the FiI'e Patients With Liver Dysfunc-
tion. The serum bilirubin on the day of oral study ranged 
from 8.1 to 17.6 mg/dl (Table 2). The predose FK 506 level 
ranged from 2.4 to 12.4 nglm!. The til1)e to reach peak 
plasma concentrations ranged from 0.5 to 2 hours. Two 
patients failed to show any peak. The mean bioavailability 
calculated was 36% (21 to 51%). Thus, the bioavailability 
was increased because of the greatly reduced intrinsic 
c1earance. 2 
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Fig 4. Aise in daily trough levels of FK 506 as the hepatic function 
deteriorated. Three days after stopping FK 506, there was still a 
significant drug level in the blood plasma. 
FK 506 PHARMACOKINETICS 
Table 3. Effect of T Tube Clamping on FK 506 Absorption 
Peak Trough 
(nQiml) (ng/ml) 
Bile Volume Open Closed Open Closed 
475 0.4 1.3 0.4 0.6 
500 0.8 0.6 0.5 0.3 
220 1.8 2.0 0.8 1.0 
490 0.5 0.7 0.2 0.4 
210 2.5 2.8 0.7 1.1 
Mean 1.2 1.5 0.5 0.7 
Effect of T Tube Clamping and Unclamping 
In the five patients, bile drainage was from 210 to 500 mild 
prior to clamping the T tube (Tables 3 and 4). There was no 
significant increase in the mean peak FK 506 concentration 
(1.2 to 1.5 ng/m!) or the mean trough FK 506 concentra-
tions (0.5 to 0.7 ng/m!) in the patients before and after T 
tube clamping (Table 3). Three patients showed a small 
increase in the dose-normalized area under the plasma 
concentration time curve (AUC), whereas in two patients 
there was a reduction in the AUC following clamping of 
the T tube (Table 4). The AUC is the index ofbioavailabil-
ity. Overall, there was no significant change in the A UC 
values. 
DISCUSSION 
The pathway of hepatic metabolism for FK 506 is not 
known precisely. The degree of jaundice (serum bilirubin 
concentration) is one of the most sensitive parameters 
reflecting hepatic damage. although it does not represent 
the overall function of the liver. Our results indicate how 
profoundly hepatic dysfunction affects the rate of metab-
olism and elimination of FK 506. 
Table 4. AUC' With T Tube Open and Closed 
Sublect 
B.D. 
R.S. 
S.H. 
H.T. 
J.S. 
Mean 
'Normalized to 1 mg. 
Open 
0.34 
0.65 
0.96 
0.16 
2.1 
0.84 
T Tube 
Closed 
0.8 
0.63 
0.76 
0.39 
2.9 
1.1 
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The increased half-life and the lower clearance of FK 
506 in patients with hepatic dysfunction is striking. The 
mean half-life of the drug was many times higher and the 
clearance of the drug was about one third or less of normal, 
depending on the severity of the liver dysfunction. 
The practical consequence is that dose adjustment must 
be made in patients when there are serious hepatic func-
tional abnormalities in order to maintain the appropriate 
plasma concentrations. These adjustments are needed 
with oral as well as with the intravenous methods of 
administration. FK 506 is a high-clearance drug. and any 
change in the intrinsic clearance of the drug in the presence 
of liver dysfunction is expected to increase the bioavail-
ability after oral administration. Additional studies should 
be done to characterize the changes in first-pass effect in 
patients with hepatic dysfunction. 
The T tube studies were also of practical importance. In 
patients with a T tube, a considerable amount of bile is 
diverted from the gastrointestinal tract, and this variable 
factor greatly influences the absorption of Cy A. 7 The lack 
of any significant change in the trough. peak, and bioavail-
ability of FK 506 in the presence or absence of biliary 
diversion is an important management advantage. 
CONCLUSION 
Following intravenous FK 506 in the presence of moder-
ate-to-severe hepatic dysfunction (serum bilirubin > 2 
mg/dl). the metabolism of the drug was affected. The 
half-life of the drug after the distribution phase was pro-
longed. and the clearance was reduced. The daily trough 
concentrations were increased. Following oral administra-
tion of the drug. the bioavailability also is increased. 
Clamping of the T tube does not alter the absorption of FK 
506. 
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